{
    "title": "114_hr639",
    "content": "The Act is titled the \"Improving Regulatory Transparency for New Medical Therapies Act.\" It amends the Federal Food, Drug, and Cosmetic Act regarding the scheduling of substances in new FDA-approved drugs. The Federal Food, Drug, and Cosmetic Act is amended to delay the approval of a drug application until an interim final rule controlling the drug is issued under the Controlled Substances Act. The Secretary will issue a scientific and medical evaluation and recommend controls under the Controlled Substances Act before approving a drug application. Approval will only occur after the interim final rule controlling the drug is issued. The \"date of approval\" is defined as the later of the application approval date or the issuance of the interim final rule. The \"date of approval\" under the Controlled Substances Act is defined as the later of the application approval date or the issuance of the interim final rule controlling the drug. The effective date of approval for biological products under the Controlled Substances Act is determined by the issuance of the interim final rule controlling the drug. The approval of a biological product under the Controlled Substances Act is delayed until the interim final rule controlling the product is issued. The date of approval is determined by the issuance of the rule. The approval of a biological product under the Controlled Substances Act is delayed until the interim final rule controlling the product is issued. The date of approval is determined by the issuance of the rule, as specified in section 201(j) of the Act. The approval date of a biological product under the Controlled Substances Act is determined by the issuance of the interim final rule controlling the product. The approval date of a drug under the Controlled Substances Act is contingent on the issuance of the interim final rule controlling the drug. The Secretary will issue a scientific and medical evaluation and recommend controls under the Controlled Substances Act before approving an application. The approval date is determined by the later of the application approval or the issuance of the interim final rule. The approval date for a drug application is determined by the later of the application approval under subsection (b) or the issuance of the interim final rule controlling the drug. Conditional approval of a drug application will not take effect until the interim final rule controlling the drug is issued under the Controlled Substances Act. The Secretary plans to issue a scientific and medical evaluation and recommend controls under the Controlled Substances Act. Conditional approval of the drug application will only occur after the interim final rule for the drug is issued. The term 'date of approval' refers to the later of the conditional approval date or the issuance date of the interim final rule. The term 'date of approval' in drug applications refers to the later of the conditional approval date or the issuance date of the interim final rule under the Controlled Substances Act. The term 'date of approval' in drug applications refers to the later of the conditional approval date or the issuance date of the interim final rule under the Controlled Substances Act. In the case of a request to add a drug to the index under the Federal Food, Drug, and Cosmetic Act, a determination to grant the request shall not take place if the Secretary intends to issue a scientific and medical evaluation and recommend controls under the Controlled Substances Act. A determination to grant a request to add a drug to the index under the Federal Food, Drug, and Cosmetic Act shall not take effect until the interim final rule controlling the drug is issued in accordance with the Controlled Substances Act. The approval date for designated new animal drugs under the Federal Food, Drug, and Cosmetic Act is determined for the 7-year exclusivity period, especially for drugs under evaluation for controls under the Controlled Substances Act. The approval date for designated new animal drugs under the Federal Food, Drug, and Cosmetic Act is crucial for the 7-year exclusivity period, particularly for drugs being evaluated for controls under the Controlled Substances Act. The drug's approval status is contingent on the issuance of an interim final rule controlling the drug in accordance with section 201(j) of the Controlled Substances Act. The interim final rule controlling the drug is issued in accordance with section 201(j) of the Controlled Substances Act, with the Attorney General required to issue an interim final rule within 90 days if recommended by the Secretary of Health and Human Services. The Secretary of Health and Human Services recommends that the Attorney General control drugs in schedule II, III, IV, or V. The Attorney General must issue an interim final rule within 90 days of receiving the scientific evaluation and scheduling recommendation. The Attorney General must issue an interim final rule within 90 days of receiving the scientific evaluation and scheduling recommendation from the Secretary of Health and Human Services. The date for this action is determined by the later of receiving the scheduling recommendation or notification of drug approval. The Attorney General must issue an interim final rule within 90 days of receiving a scheduling recommendation or drug approval notification from the Secretary of Health and Human Services. The rule becomes immediately effective without needing a demonstration of good cause. The Attorney General must issue an interim final rule within 90 days of receiving a scheduling recommendation or drug approval notification. The rule becomes immediately effective without needing a demonstration of good cause and allows for public comment and hearing before issuing a final rule. The Attorney General must issue an interim final rule within 90 days of receiving a scheduling recommendation or drug approval notification, allowing for public comment and hearing before issuing a final rule. The extension of patent term under Section 156 of title 35, United States Code, is amended to include a provision for drug products described in subsection (i) to be eligible for an extension within a sixty-day period after the covered date. Additionally, a new subsection (i) is added to address notifications from the Secretary of Health and Human Services to drug sponsors. The extension of patent term under Section 156 of title 35, United States Code, is amended to include drug products eligible for an extension within sixty days after the covered date. A new subsection (i) addresses notifications from the Secretary of Health and Human Services to drug sponsors regarding controls under the Controlled Substances Act for approved or indexed drug products. The Controlled Substances Act will recommend controls for drug products approved under relevant provisions of the Public Health Service Act or Federal Food, Drug, and Cosmetic Act, with permission for commercial marketing. The \"covered date\" refers to the later of the approval date under specific sections of the Public Health Service Act or the Federal Food, Drug, and Cosmetic Act. The \"covered date\" for drug products with commercial marketing permission is determined by the approval date under specific sections of the Public Health Service Act or the Federal Food, Drug, and Cosmetic Act. The Controlled Substances Act is amended to enhance new drug development by allowing registration for manufacturing controlled substances for clinical trials. SEC. 3. ENHANCING NEW DRUG DEVELOPMENT. Amends Section 303 of the Controlled Substances Act to expedite registration for manufacturing controlled substances for clinical trials. The Attorney General must register the applicant within 180 days of accepting the application for manufacturing a controlled substance for clinical trials. If the substance is for use only in a clinical trial, registration must be done within 90 days after the application is accepted. The Attorney General must issue a notice of application within 90 days of accepting it for filing. Within 90 days after the comment period ends, the applicant will be registered or served an order to show cause. Additionally, there are amendments regarding re-exportation among members of the European Economic Area in the Controlled Substances Import and Export Act. SEC. 4. RE-EXPORTATION AMONG MEMBERS OF THE EUROPEAN ECONOMIC AREA. Section 1003 of the Controlled Substances Import and Export Act is amended to allow controlled substances to be exported from a second country in the European Economic Area to another country. The Controlled Substances Import and Export Act (U.S.C. 953) is amended to allow re-exportation of controlled substances among members of the European Economic Area. This includes exporting from one country to another within the EEA, with certain conditions. The Controlled Substances Import and Export Act is amended to allow re-exportation of controlled substances among members of the European Economic Area, with specific conditions for exporting between countries within the EEA. Controlled substances can be exported within the European Economic Area under specific conditions, ensuring compliance with regulations in each country involved. Controlled substances can be exported within the European Economic Area under specific conditions, ensuring compliance with regulations in each country involved. The exported substance must meet conditions applicable to each subsequent country it is exported to, and re-exportation among members of the European Economic Area requires delivery of information to the Attorney General within 30 days. Exportation within the European Economic Area requires documentation and information delivery to the Attorney General within 30 days. The Attorney General must receive documentation and information for re-exportation within the European Economic Area, with limitations on regulations for controlled substances. The Attorney General is prohibited from creating regulations that hinder the re-exportation of controlled substances among European Economic Area countries, including restrictions on timing and information disclosure. The Attorney General cannot impose restrictions on the timing or information disclosure for re-exportation of controlled substances among European Economic Area countries. The curr_chunk is about the roles of the Speaker of the House of Representatives and the Vice President of the United States as President of the Senate."
}